scholarly journals Cognitive Complaints After Breast Cancer Treatments: Examining the Relationship With Neuropsychological Test Performance

2013 ◽  
Vol 105 (11) ◽  
pp. 791-801 ◽  
Author(s):  
Patricia A. Ganz ◽  
Lorna Kwan ◽  
Steven A. Castellon ◽  
Amy Oppenheim ◽  
Julienne E. Bower ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Test Performance ◽  
Neuropsychological Test ◽  
Cognitive Complaints ◽  
Cancer Treatments ◽  
The Relationship

scholarly journals Brain Structure and Function Differences in Monozygotic Twins: Possible Effects of Breast Cancer Chemotherapy

2007 ◽  
Vol 25 (25) ◽  
pp. 3866-3870 ◽  
Author(s):  
Robert J. Ferguson ◽  
Brenna C. McDonald ◽  
Andrew J. Saykin ◽  
Tim A. Ahles
Keyword(s):  
Breast Cancer ◽  
Cognitive Dysfunction ◽  
Test Performance ◽  
Breast Cancer Survivors ◽  
Neuropsychological Test ◽  
Monozygotic Twins ◽  
Self Report ◽  
Functional Health ◽  
Cognitive Complaints ◽  
Breast Cancer Chemotherapy

Purpose Adjuvant chemotherapy has been associated with mild cognitive decline among a subset of breast cancer survivors. Late cognitive effects after chemotherapy can have a deleterious impact on survivor quality of life and functional health; however, the etiology of chemotherapy-related cognitive dysfunction remains unknown. Patients and Methods We present a case of monozygotic twins who are discordant for breast cancer and chemotherapy exposure (ie, one twin contracted breast cancer and underwent chemotherapy, and the other had no breast cancer). As part of a larger study, each was evaluated with standardized, self-report measures of cognitive function, standard neuropsychological tests, and structural and functional magnetic resonance imaging (MRI). Results Results indicated small differences in neuropsychological test performance but striking contrasts in self-reported cognitive complaints and structural and functional MRI images. Specifically, the twin who underwent chemotherapy had substantially more subjective cognitive complaints, more white matter hyperintensities on MRI, and an expanded spatial extent of brain activation during working memory processing than her nonaffected twin. Conclusion This case illustrates possible physiologic mechanisms that could produce long-term cognitive complaints among chemotherapy recipients and help formulate hypotheses for further empirical study in the area of chemotherapy-associated cognitive dysfunction.

scholarly journals The Gut Microbiota: A Potential Gateway to Improved Health Outcomes in Breast Cancer Treatment and Survivorship

2020 ◽  
Vol 21 (23) ◽  
pp. 9239
Author(s):  
Kara Sampsell ◽  
Desirée Hao ◽  
Raylene A. Reimer
Keyword(s):  
Breast Cancer ◽  
Gut Microbiota ◽  
Response To Treatment ◽  
Physical And Mental Health ◽  
Cancer Treatments ◽  
Probiotic Supplementation ◽  
Treatment Side Effects ◽  
Biological Environment ◽  
Endocrine Signaling ◽  
The Relationship

Breast cancer is the most frequently diagnosed cancer in women worldwide. The disease and its treatments exert profound effects on an individual’s physical and mental health. There are many factors that impact an individual’s risk of developing breast cancer, their response to treatments, and their risk of recurrence. The community of microorganisms inhabiting the gastrointestinal tract, the gut microbiota, affects human health through metabolic, neural, and endocrine signaling, and immune activity. It is through these mechanisms that the gut microbiota appears to influence breast cancer risk, response to treatment, and recurrence. A disrupted gut microbiota or state of ‘dysbiosis’ can contribute to a biological environment associated with higher risk for cancer development as well as contribute to negative treatment side-effects. Many cancer treatments have been shown to shift the gut microbiota toward dysbiosis; however, the microbiota can also be positively manipulated through diet, prebiotic and probiotic supplementation, and exercise. The objective of this review is to provide an overview of the current understanding of the relationship between the gut microbiota and breast cancer and to highlight potential strategies for modulation of the gut microbiota that could lead to improved clinical outcomes and overall health in this population.

Associations between morning–evening chronotype, fatigue, and QOL in breast cancer survivors.

2016 ◽  
Vol 34 (3_suppl) ◽  
pp. 246-246 ◽  
Author(s):  
Oxana Palesh ◽  
M. Melissa Packer ◽  
Holly George ◽  
Cheryl Koopman ◽  
Pasquale F. Innominato
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Bright Light ◽  
Well Being ◽  
Cancer Treatments ◽  
Significant Difference ◽  
Morning Type ◽  
The Relationship ◽  
Range Of Values

246 Background: Emerging evidence suggests that circadian disruption is associated with cancer and cancer treatments. Chronotype is defined as a behaviorally manifested preference for a certain timing of sleep and activity. Previous studies have revealed that living out of sync from one’s innate chronotype can have detrimental effects on one’s health. Although there has been research examining the associations between chronotype and health, not much is known about the relationship between chronotype, fatigue, and QOL in cancer survivors. Methods: 68 Breast cancer survivors completed questionnaires to assess their chronotype (Horne-Ostberg), to rate their fatigue (MDASI), and to evaluate their QOL (FACIT). The Horne-Ostberg questionnaire yields a range of values indicating survivors’ preference for early or late activity. The study sample was divided by terciles according to survivors’ “morningness” or “eveningness” preferences (i.e., chronotypes). Results: Morning chronotype was associated with significantly less severe tiredness and drowsiness as well as significantly better physical well-being and fatigue subscale scores as compared to evening chronotype. Tiredness median (M) scores were highest for evening chronotype (M=5.5), moderate for mid-range chronotype (M=4.5), and lowest for morning chronotype (M=3.0), a significant difference (p=0.046). Drowsiness scores were highest for evening chronotype (median=6.0), moderate for mid-range chronotype (M=4.0), and lowest for morning chronotype (M=3.0), p=0.046. The median score for physical well-being was significantly lower for evening compared to morning chronotypes (22.5 vs. 25.0, p=0.038) and morning types reported significantly better health in respect to fatigue compared to evening types (40.5 vs. 35.5, p=0.045). Conclusions: Survivors with early chronotype (early to bed, early to rise) reported less fatigue, drowsiness, and better overall physical well-being. While chronotype is believed to be genetically driven, certain behavioral, pharmacological, and bright light modifications can be used to help patients shift their circadian rhythm towards earlier morning type and may experience improvements in physical well-being.

scholarly journals Cognitive Function After the Initiation of Adjuvant Endocrine Therapy in Early-Stage Breast Cancer: An Observational Cohort Study

2014 ◽  
Vol 32 (31) ◽  
pp. 3559-3567 ◽  
Author(s):  
Patricia A. Ganz ◽  
Laura Petersen ◽  
Steven A. Castellon ◽  
Julienne E. Bower ◽  
Daniel H.S. Silverman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Depressive Symptoms ◽  
Endocrine Therapy ◽  
Test Performance ◽  
Early Stage ◽  
Self Report ◽  
Early Stage Breast Cancer ◽  
Linear Regression Models ◽  
Cognitive Complaints ◽  
Observational Cohort

Purpose This report examines cognitive complaints and neuropsychological (NP) testing outcomes in patients with early-stage breast cancer after the initiation of endocrine therapy (ET) to determine whether this therapy plays any role in post-treatment cognitive complaints. Patients and Methods One hundred seventy-three participants from the Mind Body Study (MBS) observational cohort provided data from self-report questionnaires and NP testing obtained at enrollment (T1, before initiation of ET), and 6 months later (T2). Bivariate analyses compared demographic and treatment variables, cognitive complaints, depressive symptoms, quality of life, and NP functioning between those who received ET versus not. Multivariable linear regression models examined predictors of cognitive complaints at T2, including selected demographic variables, depressive symptoms, ET use, and other medical variables, along with NP domains that were identified in bivariate analyses. Results Seventy percent of the 173 MBS participants initiated ET, evenly distributed between tamoxifen or aromatase inhibitors. ET-treated participants reported significantly increased language and communication (LC) cognitive complaints at T2 (P = .003), but no significant differences in NP test performance. Multivariable regression on LC at T2 found higher LC complaints significantly associated with T1 LC score (P < .001), ET at T2 (P = .004), interaction between ET and past hormone therapy (HT) (P < .001), and diminished improvement in NP psychomotor function (P = .05). Depressive symptoms were not significant (P = .10). Conclusion Higher LC complaints are significantly associated with ET 6 months after starting treatment and reflect diminished improvements in some NP tests. Past HT is a significant predictor of higher LC complaints after initiation of ET.

C-14American Indian Heritage and the Relationship to Neuropsychological Test Performance

2015 ◽  
Vol 30 (6) ◽  
pp. 568.1-568
Author(s):  
H Wadsworth ◽  
J Galusha-Glasscock ◽  
K Womack ◽  
C Cullum
Keyword(s):  
Test Performance ◽  
Neuropsychological Test ◽  
The Relationship

Behavior Rating Inventory of Executive Function Adult Version in Patients with Neurological and Neuropsychiatric Conditions: Symptom Levels and Relationship to Emotional Distress

2016 ◽  
Vol 22 (6) ◽  
pp. 682-694 ◽  
Author(s):  
M. Løvstad ◽  
S. Sigurdardottir ◽  
S. Andersson ◽  
V.A. Grane ◽  
T. Moberget ◽  
...  
Keyword(s):  
Executive Function ◽  
Emotional Distress ◽  
Test Performance ◽  
Normative Data ◽  
Rating Scales ◽  
Neuropsychological Test ◽  
Behavior Rating ◽  
Behavior Rating Inventory ◽  
And Performance ◽  
The Relationship

AbstractObjectives:The present study explored the level of self-and informant reported executive functioning in daily living using the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) in a large sample comprising healthy adults and patient cohorts with neurological and neuropsychiatric disorders. The relationship to neuropsychological test performance and self-reported emotional distress was explored, as well as the applicability of U.S. normative data.Methods:Scores on the self- and informant reported BRIEF-A are presented, along with scores on standardized cognitive tests, and on rating scales of self-reported emotional distress in a Norwegian healthy comparison group (n=115), patients with severe traumatic brain injury (n=125), focal frontal lobe damage (n=29), focal cerebellar lesion (n=24), Parkinson’s disease (n=42), attention deficit hyperactivity disorder (n=34), type II bipolar disorder (n=21), and borderline personality disorder (n=18).Results:Strong associations were observed between the BRIEF-A and emotional distress in both the healthy group and in neurological groups, while no or weak relationships with IQ and performance-based tests of executive function were seen. The relationship between BRIEF-A and emotional distress was weaker in the neuropsychiatric patient groups, despite high symptom load in both domains. Healthy participants tended to have BRIEF-A scores 1/2–3/4SDbelow the U.S. normative mean ofTscore=50.Conclusions:The study demonstrates the need to interpret BRIEF-A results within a broad differential diagnostic context, where measures of psychological distress are included in addition to neuropsychological tests. Uncertainty about the appropriateness of U.S. normative data in non-U.S. countries adds to the need for interpretive caution. (JINS, 2016,22, 682–694)

Sign in / Sign up

Export Citation Format

Share Document